HIGHLIGHTS
SUMMARY
Naïve untreated MM patients have an increased inherent risk for venous thrombosis which further increases during anti-MM treatment. To date, several clinical studies suggest that patients with MGUS may as well carry a higher venous thromboembolism (VTE) risk compared to the general population. The M-protein has known thrombogenic properties that have a proven causative relationship with thrombotic events, and have been described in otherwise asymptomatic MGUS patients or in patients with MG not fulfilling treatment criteria. Currently, prophylaxis and treatment of thrombotic events in MGUS patients and in untreated MG patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.